Study of Daily Application of Nestorone® (NES) and Testosterone (T) Combination Gel for Male Contraception

PHASE2CompletedINTERVENTIONAL
Enrollment

420

Participants

Timeline

Start Date

October 25, 2018

Primary Completion Date

September 6, 2024

Study Completion Date

September 6, 2024

Conditions
HealthyMenMale Contraception
Interventions
DRUG

Nestorone + Testosterone Combination Gel

The combined gel is a transdermal treatment that will be applied daily for 52 weeks to a male subject's arms and shoulders. The formulation will be a hydro alcoholic gel. About 9 to 14% of the steroid (T or NES) in the gel applied is available to the body. The amount of gel to be applied each application will be approximately 5 mL in volume.

Trial Locations (17)

19104

University of Pennsylvania Medical Center, Philadelphia

23507

Eastern Virginia Medical School-EVMS Obstetrics & Gynecology, Norfolk

40138

University of Bologna, Italy, Bologna

66160

University of Kansas, Kansas City

80230

Comprehensive Women's Health Center, Denver

84132

University of Utah, Salt Lake City

90509

The Lunquist Institute at Harbor-UCLA Medical Center, Torrance

95817

UC Davis Health, Sacramento

97239

Oregon Health & Science University, Portland

98195

University of Washington Medical Center & Health Sciences, Seattle

7650672

Centro de Medicina Reproductiva Shady Grove Chile, Santiago

8320000

Chilean Institute of Reproductive Medicine, Santiago

00202

Kenyatta National Hospital, Nairobi

Unknown

Karolinska Institutet, Stockholm

EH 16 4SA

University of Edinburgh, Edinburgh

M13 9WL

University of Manchester, UK, Manchester

00000

Spilhaus Clinical Research Site, Harare

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Population Council

OTHER

collaborator

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

NIH

lead

Premier Research

OTHER